CHGCF: AI 评分 55/100 — AI 分析 (4月 2026)

Chugai Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company based in Japan, focused on innovative prescription medicines. As a subsidiary of Roche Holding Ltd., Chugai leverages strategic alliances and collaborations to develop and commercialize pharmaceutical products globally.

Key Facts: AI Score: 55/100 Sector: Healthcare

公司概况

概要：

Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche, develops and markets prescription pharmaceuticals, primarily in oncology, osteoporosis, and other specialty therapeutic areas. With a strong presence in Japan and strategic global alliances, Chugai focuses on innovative, science-based solutions, maintaining a robust pipeline of development product candidates.

CHGCF是做什么的？

Founded in 1925 and headquartered in Chuo, Japan, Chugai Pharmaceutical Co., Ltd. has evolved into a prominent research-based pharmaceutical company. The company engages in the research, development, manufacture, sale, importation, and exportation of pharmaceutical products, both in Japan and internationally. Chugai's diverse portfolio includes products for oncology, such as Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva. It also offers treatments for osteoporosis, including Actemra, Edirol, and Bonviva, as well as Mircera for erythropoiesis, Oxarol for secondary hyperparathyroidism, and other diseases with drugs like Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, and Vabysmo, and Enspryng. Chugai's strategic alliance with Roche Group is central to its global operations, providing access to resources and collaborative research opportunities. The company also fosters joint research initiatives with academia to drive innovation. With a focus on oncology, immunology, neuroscience, hematology, and ophthalmology, Chugai continues to develop a robust pipeline of product candidates aimed at addressing unmet medical needs.

CHGCF的投资论点是什么？

Chugai Pharmaceutical presents a compelling investment case driven by its strong oncology portfolio and strategic alliance with Roche. With a profit margin of 34.5% and a gross margin of 71.1%, the company demonstrates financial strength. A dividend yield of 2.91% offers investors income. Upcoming catalysts include the potential approval and launch of new pipeline products in oncology, immunology, and neuroscience. Potential risks include regulatory challenges and competition from biosimilars, which could impact revenue from key products. The company's commitment to research and development, combined with its established market presence, positions it for sustained growth.

CHGCF在哪个行业运营？

Chugai Pharmaceutical operates within the global pharmaceutical industry, characterized by intense competition, stringent regulatory oversight, and continuous innovation. The market is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Chugai's focus on oncology and specialty therapeutic areas aligns with key growth segments in the industry. Competitors include companies like CMXHF (CM Life Science), DSKYF (Daiichi Sankyo), DSNKY (Daiichi Sankyo Company, Limited), GLAXF (GlaxoSmithKline), and HOCPY (Hoya Corp), each vying for market share through product innovation and strategic partnerships.

Drug Manufacturers - General

Healthcare

CHGCF有哪些增长机遇？

Expansion of Oncology Portfolio: Chugai's oncology franchise, featuring drugs like Avastin, Tecentriq, and Alecensa, represents a significant growth opportunity. The global oncology market is projected to reach $286.6 billion by 2031, growing at a CAGR of 9.4% from 2022. By continuing to develop and commercialize innovative cancer therapies, Chugai can capture a larger share of this expanding market.
Development of Novel Immunotherapies: Chugai is actively developing novel immunotherapies targeting various autoimmune and inflammatory diseases. The global immunotherapy market is expected to reach $300 billion by 2030. Successful development and commercialization of these therapies could significantly boost Chugai's revenue and market position.
Advancements in Neuroscience: Chugai is investing in research and development of treatments for neurological disorders, including Alzheimer's disease and multiple sclerosis. The neuroscience market is projected to reach $45 billion by 2028. Breakthroughs in this area could provide substantial growth opportunities for Chugai.
Strategic Partnerships and Collaborations: Chugai's strategic alliance with Roche provides access to resources, technologies, and global markets. By continuing to forge strategic partnerships and collaborations with other pharmaceutical companies and research institutions, Chugai can accelerate its drug development efforts and expand its market reach.
Geographic Expansion: While Chugai has a strong presence in Japan, expanding its operations into other key markets, such as the United States and Europe, represents a significant growth opportunity. This expansion could involve establishing local subsidiaries, forging distribution agreements, or acquiring existing pharmaceutical companies.

Market capitalization of $98.34 billion reflects Chugai's significant presence in the pharmaceutical industry.
P/E ratio of 35.50 indicates investor expectations for future earnings growth.
Profit margin of 34.5% demonstrates strong profitability and operational efficiency.
Gross margin of 71.1% highlights the company's ability to maintain high pricing and manage production costs effectively.
Dividend yield of 2.91% provides an attractive return for income-seeking investors.

CHGCF提供哪些产品和服务？

Researches and develops pharmaceutical products.
Manufactures pharmaceutical drugs.
Sells and markets pharmaceutical products in Japan and internationally.
Imports and exports pharmaceutical products.
Focuses on oncology, osteoporosis, and other specialty therapeutic areas.
Collaborates with Roche Group and academia for research and development.

CHGCF如何赚钱？

Develops and patents innovative pharmaceutical products.
Manufactures drugs in-house or through contract manufacturers.
Markets and sells drugs through its own sales force and distribution network.
Generates revenue through product sales and licensing agreements.

Hospitals and clinics
Pharmacies
Healthcare providers
Patients

Strong research and development capabilities
Strategic alliance with Roche Group
Established market presence in Japan
Patent protection for innovative drugs

什么因素可能推动CHGCF股价上涨？

Upcoming: Potential approval and launch of new pipeline products in oncology.
Upcoming: Development and commercialization of novel immunotherapies.
Ongoing: Strategic alliance with Roche Group driving innovation and market access.
Ongoing: Expansion of geographic presence in key markets.
Ongoing: Advancements in neuroscience research and development.

CHGCF的主要风险是什么？

Potential: Competition from biosimilars impacting revenue from key products.
Potential: Regulatory challenges and delays in drug approval processes.
Potential: Pricing pressures from healthcare payers.
Ongoing: Dependence on Roche for certain resources and technologies.
Ongoing: Economic downturns and market volatility affecting financial performance.

CHGCF的核心优势是什么？

Strong oncology portfolio
Strategic alliance with Roche
High profit margin
Robust pipeline of product candidates

CHGCF的劣势是什么？

Dependence on Roche for certain resources and technologies
Exposure to patent expiration risks
Limited geographic diversification
Vulnerability to regulatory changes

CHGCF有哪些机遇？

Expansion into new therapeutic areas
Geographic expansion into key markets
Development of novel immunotherapies
Strategic acquisitions and partnerships

CHGCF面临哪些威胁？

Competition from biosimilars
Pricing pressures from healthcare payers
Regulatory challenges and delays
Economic downturns and market volatility

CHGCF的竞争对手是谁？

CM Life Science — Focuses on generic pharmaceuticals and biosimilars. — (CMXHF)
Daiichi Sankyo — Global pharmaceutical company with a focus on oncology and cardiovascular diseases. — (DSKYF)
Daiichi Sankyo Company, Limited — Offers a broad range of pharmaceutical products. — (DSNKY)
GlaxoSmithKline — Global healthcare company with a diverse portfolio of pharmaceuticals, vaccines, and consumer healthcare products. — (GLAXF)
Hoya Corp — Diversified technology company with healthcare-related products. — (HOCPY)

Key Metrics

MoonshotScore: 55/100

Company Profile

CEO: Osamu Okuda
Headquarters: Chuo, JP
Employees: 5,026
Founded: 2012

AI Insight

AI analysis pending for CHGCF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Chugai Pharmaceutical Co., Ltd. do?

Chugai Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company that discovers, develops, manufactures, and markets innovative prescription medicines. The company focuses primarily on oncology, osteoporosis, and other specialty therapeutic areas. As a subsidiary of Roche Holding Ltd., Chugai leverages strategic alliances and collaborations to develop and commercialize pharmaceutical products globally, addressing unmet medical needs and improving patient outcomes.

What do analysts say about CHGCF stock?

Analyst coverage of CHGCF is limited due to its OTC listing and status as a subsidiary of Roche. However, key valuation metrics such as the P/E ratio of 35.50 and dividend yield of 2.91% provide insights into investor expectations and potential returns. Growth considerations include the company's strong oncology portfolio, strategic alliance with Roche, and pipeline of product candidates. Investors should conduct their own due diligence and consider their risk tolerance before investing.

What are the main risks for CHGCF?

The main risks for Chugai Pharmaceutical Co., Ltd. include competition from biosimilars, which could impact revenue from key products like Avastin and Rituxan. Regulatory challenges and delays in drug approval processes also pose a risk. Additionally, pricing pressures from healthcare payers and economic downturns could affect the company's financial performance. Investors should carefully consider these risks before investing in CHGCF.